相关临床试验
290
15 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1798
进行中（未招募）
7
2.4%
已完成
146
50.3%
Enrolling By Invitation
4
1.4%
尚未招募
4
1.4%
招募中
47
16.2%
终止
33
11.4%
Unknown
2
0.7%
撤回
47
16.2%
暂无批准数据
- The National Institute of General Medical Sciences awarded $11.6 million over five years to the University of Louisville to establish the Nutrition and Metabolic Health Center (NMHC). - The university committed an additional $7.25 million to the center, which will study how food, metabolism, and environmental exposures affect chronic diseases such as diabetes, heart disease, and liver dysfunction. - The CoBRE grant will fund four early-career research projects and expand core facilities in data management/AI, multi-omics, and translational metabolic phenotyping. - Center leaders cited poor diet as the leading cause of premature death worldwide, contributing to over 11 million deaths annually.
- A NIH-funded clinical trial found that symptom-based opioid dosing for newborns with neonatal opioid withdrawal syndrome (NOWS) reduced hospital stays by two days compared to scheduled dosing approaches. - The OPTimize NOW study involving 383 infants showed that "as-needed" dosing based on withdrawal symptoms helped babies stop medication sooner while minimizing drug exposure. - The symptom-based approach was effective only when combined with the family-centered Eat, Sleep, Console (ESC) care model, not with traditional healthcare provider-centric approaches. - Several hospitals have already adopted this strategy following the trial results, with researchers believing it could inform broader clinical practice changes.
- Elephas Biosciences appointed Premal Patel, MD, PhD, as Chief Medical Officer and Dr. Michael Giordano to its Scientific Advisory Board to strengthen clinical leadership as the company advances toward commercial launch. - The company announced a new research partnership with the University of Louisville to conduct three Investigator-Initiated Trials evaluating combination therapy of surgical intervention and immunotherapy in colorectal, liver, and pancreatic cancers. - The Elephas Live™ Platform addresses a critical unmet need in oncology by providing real-time functional response data, as currently only one in five cancer patients benefit from immunotherapy. - Recent milestones include a peer-reviewed publication in the Journal of Translational Medicine and the completion of a $42 million financing round, positioning the company for commercial growth.
- Breath Diagnostics' OneBreath™ technology demonstrated the ability to predict pneumonia onset in cardiac surgery patients days before clinical symptoms emerge, achieving an AUROC of 0.833 in a study published in The Journal of Thoracic and Cardiovascular Surgery. - The prospective study of 75 cardiac surgery patients showed that volatile organic compounds in exhaled breath can serve as reliable biomarkers for future disease, with 10 patients developing postoperative pneumonia. - This represents the first demonstration that breath analysis combined with machine learning can both diagnose and predict pneumonia, potentially transforming postoperative care and enabling earlier interventions. - The technology offers non-invasive testing independent of patient history and could be extended to other diseases including lung infections, cancer, and inflammatory disorders.
